Neurocrine Biosciences, Inc.

Icos Corporation

Deltagen Research Labs, LLC

Graham Beaton

Timothy Richard Coon

Martin W Rowbottom

Warren Stanfield Wade

Mi Chen

Neil Ashweek

Todd Ewing

Yun-Fei Zhu

Wanlong Jiang

Willy Moree

Liren Zhao

Richard B Lowe

Nicole Smith

Jinghua Yu

Kerry W Fowler

Jaimie Karyn Rueter

Danwen Huang

Qin Jiang

Pavel E Zhichkin

Russell Dahl

Wilna J Moree

David L McElligott

David John Fairfax

Erik Christenson

Phyllis S Goldman

Helge A Reisch

Florence Jovic

Wilna (Willy) J Moree

Anthony J Demaggio

Dan Herendeen

Jaimie E Bertino

Lisa H Bourdon

Ren Hua Song

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R, R, R, R, R, R, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R, R, R, R, R, R, and A are as defined herein, including stereoisomers, esters, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure, wherein R, R, R, R, R, R, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof. 

Compounds having the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts, esters and solvates thereof, wherein R, R, R, R, L, Land n are as defined herein. Such compounds generally function as Hreceptor ligands, and thus have utility as sleep inducing agents. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.

Sleep inducing compounds and methods relating thereto

The present invention provides compounds comprising a bicyclic aryl moiety, such as 2H-phthalazin-1-one or derivatives thereof, compositions comprising the same, and methods for producing and using the same. In particular, the present invention provides compounds of the formula:or a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof; where Q, Qand Y are those defined herein.

PARP inhibitors

Growing community of inventors

Poway, CA, United States of America

Graham Beaton